Rhodes Jason P

DirectorDyne Therapeutics, Inc. (DYN) · full profile →Form 4 · filed May 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.9M
Net Open-Market Flow
-$1.9M
Transactions
12
12 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 6, 2026Sell(S)17K$18.18$313K1.1M
May 6, 2026Sell(S)428$18.18$8K8K
May 6, 2026Sell(S)22K$18.18$399K1.5M
May 6, 2026Sell(S)44K$18.18$793K4.9M
May 5, 2026Sell(S)60$18.03$1K8K
May 5, 2026Sell(S)3K$18.03$55K1.6M
May 5, 2026Sell(S)6K$18.03$110K4.9M
May 5, 2026Sell(S)2K$18.03$43K1.2M
May 4, 2026Sell(S)3K$18.00$56K1.6M
May 4, 2026Sell(S)2K$18.00$44K1.2M
May 4, 2026Sell(S)61$18.00$1K8K
May 4, 2026Sell(S)6K$18.00$112K4.9M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001577014-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly: